LONDON, 5 July, 2010 – Panmure Gordon & Co. is pleased to announce its appointment joint broker Renovo Group plc (RNVO.L) with immediate effect.

Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.

Welcoming Renovo as a client, Panmure Gordon group chief executive, Tim Linacre said: “We are very pleased to welcome Renovo as an excellent addition to Panmure Gordon’s growing healthcare client list. Panmure Gordon now represents a range of pharmaceutical and medical technology firms, all of whom are investing in the development of new treatments for medical conditions affecting millions of people world-wide.”